Pulmatrix, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Pulmatrix, Inc. on April 9, 2019, covering events occurring on April 3, 2019, and April 8, 2019. The filing details the entry into a material definitive agreement for an underwritten public offering of equity securities.
Key Financial Metrics and Transaction Details
The Company completed a public offering with the following financial terms:
- Securities Issued: 1,719,554 Common Units (one share of common stock and one warrant) and 8,947,112 Pre-Funded Units (one pre-funded warrant and one warrant).
- Offering Prices: $1.35 per Common Unit and $1.34 per Pre-Funded Unit.
- Over-Allotment: The underwriter exercised its option in full to purchase an additional 1,599,999 shares of common stock and/or Common Warrants.
- Net Proceeds: Approximately $14.8 million after deducting underwriting discounts, commissions, and estimated offering expenses.
- Underwriter Warrants: The Company issued warrants to the underwriter to purchase up to 797,334 shares of common stock at an exercise price of $1.6875 per share.
The filing does not provide specific revenue, profit, cash flow, margin, or debt figures for the reporting period, as this is a transactional filing rather than a periodic financial report.
Material Changes and Use of Proceeds
The primary material change is the significant increase in equity capital and the dilution of existing shareholders due to the issuance of new shares and warrants. The Company intends to use the net proceeds of approximately $14.8 million for:
- Research and development of therapeutic candidates, specifically the development of Pulmazole.
- Working capital and general corporate purposes.
Outlook, Risks, and Contingencies
The offering closed on April 8, 2019. The Common Warrants included in the units are immediately exercisable at $1.35 per share and expire five years from issuance. The Pre-Funded Warrants are immediately exercisable at $0.01 per share. The filing notes that the descriptions of the agreements and warrants are qualified by reference to the full text of the exhibits.
Key Facts for Investor Verification
- Verify the exact number of shares outstanding post-offering to assess dilution impact.
- Confirm the exercise dates and expiration terms for the Common Warrants ($1.35 strike) and Pre-Funded Warrants ($0.01 strike).
- Review the full Underwriting Agreement (Exhibit 1.1) for specific indemnification and termination provisions.
- Monitor the allocation of the $14.8 million net proceeds toward the development of Pulmazole.